×
S&P 500   3,821.55
DOW   30,946.99
QQQ   283.54
S&P 500   3,821.55
DOW   30,946.99
QQQ   283.54
S&P 500   3,821.55
DOW   30,946.99
QQQ   283.54
S&P 500   3,821.55
DOW   30,946.99
QQQ   283.54
NASDAQ:HOLX

Hologic Stock Forecast, Price & News

$69.78
-1.68 (-2.35%)
(As of 06/28/2022 12:00 AM ET)
Add
Compare
Today's Range
$69.70
$72.27
50-Day Range
$67.12
$79.08
52-Week Range
$66.26
$81.04
Volume
1.27 million shs
Average Volume
1.88 million shs
Market Capitalization
$17.40 billion
P/E Ratio
11.50
Dividend Yield
N/A
Price Target
$81.00
30 days | 90 days | 365 days | Advanced Chart

Receive HOLX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hologic and its competitors with MarketBeat's FREE daily newsletter.

HOLX Stock Forecast (MarketRank)

Overall MarketRank

2.42 out of 5 stars

Medical Sector

191st out of 1,433 stocks

X-Ray Apparatus & Tubes Industry

2nd out of 6 stocks

Analyst Opinion: 2.3Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 2.5 5 -4 -3 -2 -1 -
Hologic logo

About Hologic (NASDAQ:HOLX)

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus. It also offers breast imaging and analytics, such as 2D and 3D digital mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, breast biopsy site markers and localization, specimen radiology, and ultrasound and connectivity solutions; and breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology within the uterus; and Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.

HOLX Stock News Headlines

Analysts Set Hologic, Inc. (NASDAQ:HOLX) PT at $81.00
See More Headlines

Industry, Sector and Symbol

Industry
X-ray apparatus & tubes
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NASDAQ:HOLX
CUSIP
43644010
Employees
6,705
Year Founded
1985

Company Calendar

Last Earnings
4/27/2022
Today
6/28/2022
Next Earnings (Estimated)
7/27/2022
Fiscal Year End
9/30/2022

Price Target and Rating

Average Stock Price Forecast
$81.00
High Stock Price Forecast
$95.00
Low Stock Price Forecast
$75.00
Forecasted Upside/Downside
+16.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.55555555555556
Research Coverage
9 Analysts

Profitability

Net Income
$1.87 billion
Pretax Margin
36.06%

Debt

Sales & Book Value

Annual Sales
$5.63 billion
Cash Flow
$10.05 per share
Book Value
$16.64 per share

Miscellaneous

Free Float
245,541,000
Market Cap
$17.40 billion
Optionable
Optionable
Beta
1.09

Social Links















Hologic Frequently Asked Questions

Should I buy or sell Hologic stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Hologic in the last twelve months. There are currently 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" Hologic stock.
View analyst ratings for Hologic
or view top-rated stocks.

What is Hologic's stock price forecast for 2022?

9 analysts have issued 1 year price targets for Hologic's shares. Their HOLX stock forecasts range from $75.00 to $95.00. On average, they predict Hologic's share price to reach $81.00 in the next year. This suggests a possible upside of 16.1% from the stock's current price.
View analysts' price targets for Hologic
or view top-rated stocks among Wall Street analysts.

How has Hologic's stock price performed in 2022?

Hologic's stock was trading at $76.56 on January 1st, 2022. Since then, HOLX shares have decreased by 8.9% and is now trading at $69.78.
View the best growth stocks for 2022 here
.

When is Hologic's next earnings date?

Hologic is scheduled to release its next quarterly earnings announcement on Wednesday, July 27th 2022.
View our earnings forecast for Hologic
.

How were Hologic's earnings last quarter?

Hologic, Inc. (NASDAQ:HOLX) announced its earnings results on Wednesday, April, 27th. The medical equipment provider reported $2.07 EPS for the quarter, beating analysts' consensus estimates of $1.55 by $0.52. The medical equipment provider earned $1.44 billion during the quarter, compared to analyst estimates of $1.28 billion. Hologic had a trailing twelve-month return on equity of 42.26% and a net margin of 28.79%. During the same period in the prior year, the company posted $2.59 earnings per share.
View Hologic's earnings history
.

What guidance has Hologic issued on next quarter's earnings?

Hologic issued an update on its FY22 earnings guidance on Wednesday, April, 27th. The company provided EPS guidance of $5.45 to $5.65 for the period, compared to the consensus estimate of $5.13.

Who are Hologic's key executives?

Hologic's management team includes the following people:
  • Mr. Stephen P. MacMillan, Chairman, CEO & Pres (Age 58, Pay $4.51M) (LinkedIn Profile)
  • Ms. Karleen M. Oberton, Chief Financial Officer (Age 51, Pay $1.6M)
  • Mr. John M. Griffin, Gen. Counsel (Age 61, Pay $1.56M)
  • Mr. Sean S. Daugherty, Group Pres of Breast/Skeletal Health & GYN Surgical Solutions (Age 46, Pay $1.32M) (LinkedIn Profile)
  • Mr. Kevin R. Thornal, Group Pres of Global Diagnostic Solutions (Age 48, Pay $1.66M)
  • Mr. Paul Malenchini, Chief Information Officer
  • Ryan M. Simon, VP of Investor Relations
  • Ms. Elisabeth A. Hellmann, Sr. VP of Global HR & Corp. Communications (Age 53)
  • Mr. Jan Verstreken, Group Pres of International (Age 54) (LinkedIn Profile)
  • Ms. Monica Aguirre Berthelot, VP & Chief of Staff

What is Steve MacMillan's approval rating as Hologic's CEO?

283 employees have rated Hologic CEO Steve MacMillan on Glassdoor.com. Steve MacMillan has an approval rating of 79% among Hologic's employees.

What other stocks do shareholders of Hologic own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Hologic investors own include AbbVie (ABBV), NVIDIA (NVDA), Johnson & Johnson (JNJ), Alibaba Group (BABA), Walt Disney (DIS), PayPal (PYPL), Advanced Micro Devices (AMD), CVS Health (CVS), Pfizer (PFE) and Abbott Laboratories (ABT).

What is Hologic's stock symbol?

Hologic trades on the NASDAQ under the ticker symbol "HOLX."

Who are Hologic's major shareholders?

Hologic's stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (11.18%), BlackRock Inc. (8.75%), State Street Corp (4.58%), Wellington Management Group LLP (1.86%), JPMorgan Chase & Co. (1.37%) and Northern Trust Corp (1.24%). Company insiders that own Hologic stock include Benjamin Jordan Cohn, Christiana Stamoulis, Jan Verstreken, John M Griffin, Karleen Marie Oberton, Kevin R Thornal, Peter J Valenti III, Sally Crawford, Sean S Daugherty, Sean S Daugherty and Stephen P Macmillan.
View institutional ownership trends for Hologic
.

Which major investors are selling Hologic stock?

HOLX stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Goldman Sachs Group Inc., Caisse DE Depot ET Placement DU Quebec, Bellevue Group AG, Assenagon Asset Management S.A., Candriam Luxembourg S.C.A., Glenview Capital Management LLC, and Canada Pension Plan Investment Board. Company insiders that have sold Hologic company stock in the last two years include Benjamin Jordan Cohn, Jan Verstreken, Kevin R Thornal, Peter J Valenti III, and Sean S Daugherty.
View insider buying and selling activity for Hologic
or view top insider-selling stocks.

Which major investors are buying Hologic stock?

HOLX stock was purchased by a variety of institutional investors in the last quarter, including Sound Shore Management Inc. CT, Arrowstreet Capital Limited Partnership, JPMorgan Chase & Co., Alyeska Investment Group L.P., Prudential Financial Inc., Renaissance Technologies LLC, American Century Companies Inc., and GW&K Investment Management LLC.
View insider buying and selling activity for Hologic
or or view top insider-buying stocks.

How do I buy shares of Hologic?

Shares of HOLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Hologic's stock price today?

One share of HOLX stock can currently be purchased for approximately $69.78.

How much money does Hologic make?

Hologic (NASDAQ:HOLX) has a market capitalization of $17.40 billion and generates $5.63 billion in revenue each year. The medical equipment provider earns $1.87 billion in net income (profit) each year or $6.069990 on an earnings per share basis.

How many employees does Hologic have?

Hologic employs 6,705 workers across the globe.

Does Hologic have any subsidiaries?

The following companies are subsidiares of Hologic: Acessa Health, Acessa Health Inc., Beijing Hologic Technology Co. Ltd., Benassar Diagnostica-Equipamientos Medicos Unipessoal Lda., BioLucent, BioLucent LLC, Bioptics Inc., Biotheranostics Inc, Biotheranostics Inc., Bolder Surgical, Cynosure, Cytyc, Cytyc Corporation, Cytyc Prenatal Products Corp., Cytyc Surgical Products LLC, Diagenode Co. Ltd., Diagenode LLC, Diagenode SA, Diagenode SA., Diagenode SPA, Direct Radiography Corp., Emsor Sociedad de responsabilidad limitada, Faxitron Bioptics, Faxitron Bioptics LLC, Focal Therapeutics, Gen-Probe, Gen-Probe Incorporated, Gen-Probe Prodesse Inc., Gen-Probe Sales & Service Inc., Genewave SAS, Health Beacons Inc, Health Beacons Inc., Hologic (Australia & New Zealand) Pty Ltd., Hologic (MA) LLC, Hologic (Shanghai) Medical Supplies Co. Ltd., Hologic ASE LLC, Hologic Asia Limited, Hologic Asia Pacific Limited, Hologic Austria GmbH, Hologic BV, Hologic Bermuda Limited, Hologic Canada ULC, Hologic Caribbean (Barbados) SRL, Hologic Denmark ApS, Hologic Deutschland GmbH, Hologic Espana S.A., Hologic Finance Ltd., Hologic France SARL, Hologic GGO 2 LLC, Hologic GGO 3 LLP, Hologic GGO 4 LTD, Hologic Global Holding LTD, Hologic HUB LTD, Hologic Hitec-Imaging, Hologic Hitec-Imaging GmbH, Hologic Holdings Limited, Hologic IP LTD, Hologic Iberia S.L., Hologic India LLP, Hologic International Holdings B.V., Hologic Ireland Limited, Hologic Italia S.r.l., Hologic Japan KK, Hologic Latin America (Servicos Em Marketing E Negocios) Ltda., Hologic Ltd., Hologic Malaysia SDN. BHD., Hologic Medical Technologies (Beijing) Co. Ltd., Hologic Medicor GmbH, Hologic Medicor Suisse GmbH, Hologic Netherlands B.V., Hologic Nordic Holdings Oy, Hologic Singapore Pte. Ltd, Hologic Suisse SA, Hologic Surgical Products Costa Rica S.R.L., Hologic Sweden AB, Hologic Taiwan Ltd., Hologic UK Finance Ltd., Hologic US Finance Co LLC, Interlace Medical, Mobidiag Oy, Mobidiag Oy., Mobidiag UK Ltd., NXT-Dx SCRL, Navigation Three Limited, R2 Technology, Sentinelle Medical, Somatex (HK) Limited, Somatex Medical Technologies GmbH, Somatex Medical Technologies GmbH., Somatex USA Inc., SuperSonic Imagine (Shanghai) Medical Devices Co. Ltd., SuperSonic Imagine GmbH, SuperSonic Imagine HK Ltd, SuperSonic Imagine Ltd, SuperSonic Imagine SA, SuperSonic Imagine Srl, Suros Surgical Systems, Suros Surgical Systems Inc., TCT International, TCT International Co. Ltd., Third Wave Technologies, and Tridaho LLC.
Read More

When was Hologic founded?

Hologic was founded in 1985.

How can I contact Hologic?

Hologic's mailing address is 250 CAMPUS DRIVE, MARLBOROUGH MA, 01752. The official website for Hologic is www.hologic.com. The medical equipment provider can be reached via phone at (508) 263-2900, via email at [email protected], or via fax at 781-890-8031.

This page (NASDAQ:HOLX) was last updated on 6/29/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.